DE1617818B2 - Oral verabreichbare oder injizierbare antikonzeptionsmittel - Google Patents
Oral verabreichbare oder injizierbare antikonzeptionsmittelInfo
- Publication number
- DE1617818B2 DE1617818B2 DE1962S0111837 DES0111837A DE1617818B2 DE 1617818 B2 DE1617818 B2 DE 1617818B2 DE 1962S0111837 DE1962S0111837 DE 1962S0111837 DE S0111837 A DES0111837 A DE S0111837A DE 1617818 B2 DE1617818 B2 DE 1617818B2
- Authority
- DE
- Germany
- Prior art keywords
- steroid
- progestational
- oral
- conception
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 steroid ketone Chemical class 0.000 claims description 14
- 239000003433 contraceptive agent Substances 0.000 claims description 10
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 230000001072 progestational effect Effects 0.000 description 11
- 230000001833 anti-estrogenic effect Effects 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000000328 estrogen antagonist Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000186 progesterone Substances 0.000 description 8
- 229960003387 progesterone Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000000583 progesterone congener Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002254 contraceptive effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229940053934 norethindrone Drugs 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 229960001858 norethynodrel Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001911 anti-progestational effect Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101800003527 Ovulation hormone Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A43—FOOTWEAR
- A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
- A43B3/00—Footwear characterised by the shape or the use
- A43B3/12—Sandals; Strap guides thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Woven Fabrics (AREA)
- Manufacturing Of Printed Wiring (AREA)
- Phenolic Resins Or Amino Resins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB37618/61A GB1041279A (en) | 1961-10-19 | 1961-10-19 | 13-alkyl steroid ketones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE1617818A1 DE1617818A1 (de) | 1972-05-18 |
| DE1617818B2 true DE1617818B2 (de) | 1976-12-09 |
Family
ID=10397775
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19621793608 Pending DE1793608B1 (de) | 1961-10-19 | 1962-10-18 | 17alpha-Alkyl-,-Alkenyl- oder -Alkinyl-13ss-alkylgon-4-oder-5(10)-en-17ss-ol-3-one |
| DE19621618855 Granted DE1618855B2 (de) | 1961-10-19 | 1962-10-18 | Gonanen-3,17-diole und verfahren zu ihrer herstellung |
| DE1962S0111837 Granted DE1617818B2 (de) | 1961-10-19 | 1962-10-18 | Oral verabreichbare oder injizierbare antikonzeptionsmittel |
| DE1962S0082099 Expired DE1468604C2 (de) | 1961-10-19 | 1962-10-18 | Verfahren zur Herstellung von 17alpha-Alkyl-,-Alkenyl- oder -Alkinyl-13beta-alkylgon-4-oder-5(10)-en-17beta-ol-3-onen |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19621793608 Pending DE1793608B1 (de) | 1961-10-19 | 1962-10-18 | 17alpha-Alkyl-,-Alkenyl- oder -Alkinyl-13ss-alkylgon-4-oder-5(10)-en-17ss-ol-3-one |
| DE19621618855 Granted DE1618855B2 (de) | 1961-10-19 | 1962-10-18 | Gonanen-3,17-diole und verfahren zu ihrer herstellung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1962S0082099 Expired DE1468604C2 (de) | 1961-10-19 | 1962-10-18 | Verfahren zur Herstellung von 17alpha-Alkyl-,-Alkenyl- oder -Alkinyl-13beta-alkylgon-4-oder-5(10)-en-17beta-ol-3-onen |
Country Status (12)
| Country | Link |
|---|---|
| AT (4) | AT264730B (en:Method) |
| CH (5) | CH455763A (en:Method) |
| CY (1) | CY429A (en:Method) |
| DE (4) | DE1793608B1 (en:Method) |
| DK (6) | DK113641B (en:Method) |
| ES (1) | ES281669A1 (en:Method) |
| FI (4) | FI41027B (en:Method) |
| FR (1) | FR2796M (en:Method) |
| GB (2) | GB1041279A (en:Method) |
| MY (1) | MY6800075A (en:Method) |
| NO (4) | NO122643B (en:Method) |
| SE (6) | SE335526B (en:Method) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2636404C2 (de) * | 1976-08-12 | 1983-12-08 | Schering AG, 1000 Berlin und 4709 Bergkamen | Δ↑1↑↑5↑-17α-Äthinylsteroide der Östranreihe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Präparate |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| CN104926906B (zh) * | 2015-06-04 | 2016-02-10 | 保定北瑞甾体生物有限公司 | 一种17α-羟基黄体酮的制备方法 |
-
1961
- 1961-10-19 GB GB37618/61A patent/GB1041279A/en not_active Expired
- 1961-10-19 GB GB37617/61A patent/GB1041278A/en not_active Expired
-
1962
- 1962-10-15 SE SE01423/67A patent/SE335526B/xx unknown
- 1962-10-15 SE SE11024/62A patent/SE312552B/xx unknown
- 1962-10-15 SE SE11025/62A patent/SE312553B/xx unknown
- 1962-10-15 SE SE11023/62A patent/SE312551B/xx unknown
- 1962-10-15 SE SE11026/62A patent/SE313809B/xx unknown
- 1962-10-17 CH CH1562566A patent/CH455763A/de unknown
- 1962-10-17 DK DK448162AA patent/DK113641B/da unknown
- 1962-10-17 CH CH1217162A patent/CH450407A/de unknown
- 1962-10-17 CH CH1275267A patent/CH459195A/de unknown
- 1962-10-17 CH CH1562766A patent/CH432509A/de unknown
- 1962-10-17 CH CH1562666A patent/CH450408A/de unknown
- 1962-10-18 ES ES281669A patent/ES281669A1/es not_active Expired
- 1962-10-18 FI FI1879/62A patent/FI41027B/fi active
- 1962-10-18 DE DE19621793608 patent/DE1793608B1/de active Pending
- 1962-10-18 AT AT822762A patent/AT264730B/de active
- 1962-10-18 NO NO146140A patent/NO122643B/no unknown
- 1962-10-18 FI FI1876/62A patent/FI41024B/fi active
- 1962-10-18 NO NO146141A patent/NO122644B/no unknown
- 1962-10-18 FI FI1877/62A patent/FI41025B/fi active
- 1962-10-18 DK DK449662AA patent/DK115549B/da unknown
- 1962-10-18 DE DE19621618855 patent/DE1618855B2/de active Granted
- 1962-10-18 DK DK449562AA patent/DK121228B/da unknown
- 1962-10-18 DE DE1962S0111837 patent/DE1617818B2/de active Granted
- 1962-10-18 FI FI1878/62A patent/FI41026B/fi active
- 1962-10-18 NO NO146143A patent/NO122646B/no unknown
- 1962-10-18 NO NO146142A patent/NO122645B/no unknown
- 1962-10-18 DK DK449762AA patent/DK115621B/da unknown
- 1962-10-18 DE DE1962S0082099 patent/DE1468604C2/de not_active Expired
- 1962-10-19 AT AT825862A patent/AT256356B/de active
- 1962-10-19 AT AT825662A patent/AT256354B/de active
- 1962-10-19 AT AT825762A patent/AT256355B/de active
-
1963
- 1963-01-16 FR FR921556A patent/FR2796M/fr not_active Expired
-
1966
- 1966-05-02 SE SE05984/66A patent/SE340619B/xx unknown
-
1968
- 1968-01-15 CY CY42968A patent/CY429A/xx unknown
- 1968-12-31 MY MY196875A patent/MY6800075A/xx unknown
-
1969
- 1969-04-24 DK DK227069AA patent/DK129652B/da unknown
-
1970
- 1970-06-30 DK DK339670AA patent/DK124753B/da unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69118494T2 (de) | Kontrazeptionsverfahren und Schema | |
| DE69118493T2 (de) | Orales Kontrazeptin mit niedrigem Östrogen-Enthalt | |
| DE68928897T2 (de) | Verfahren und system zur empfängnisverhütung | |
| DE69532894T2 (de) | Verfahren zur empfängnisverhütung | |
| EP0310541B1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Geburtseinleitung und zum Schwangerschaftsabbruch sowie zur Behandlung gynäkologischer Störungen | |
| EP0148724B1 (de) | Mehrstufenkombinationspräparat und seine Verwendung zur oralen Kontrazeption | |
| DE3856508T2 (de) | Oestrogen und Progestin enthaltende Verhütungspackungen | |
| DE69710896T2 (de) | Progestogen-anti-progestogen therapien | |
| EP0868188B1 (de) | Kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen | |
| DE69327319T2 (de) | Minimierung von mit progesteron verbundenen durchbruckblutungen | |
| DE2365103A1 (de) | Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten | |
| DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
| DE4411585A1 (de) | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption | |
| DE2310963A1 (de) | Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten | |
| DE69721314T2 (de) | Hormonzusammensetzung welche ein östrogenes mittel und ein progestatives mittel enthält | |
| EP0787002B1 (de) | Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle | |
| DE2645307C2 (en:Method) | ||
| EP0871453A1 (de) | Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption | |
| DE2431704A1 (de) | Stufenkombinationspraeparate per kontrazeption | |
| DE3787386T2 (de) | In der Behandlung von Östrogeninsuffizienz zu verwendende Zusammensetzung. | |
| DE102004026670A1 (de) | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat | |
| DE69027028T2 (de) | Als männliches kontrazeptikum verwendbare zusammensetzungen | |
| DD238921A5 (de) | Verfahren zur herstellung einer kontrazeptiven synergistischen zusammensetzung | |
| DE1617818B2 (de) | Oral verabreichbare oder injizierbare antikonzeptionsmittel | |
| DE1617818C3 (de) | Oral verabreichbare oder injizierbare Antikonzeptionsmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| E77 | Valid patent as to the heymanns-index 1977 |